ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib, the first-in-class BCR-ABL tyrosine kinase inhibitor (TKI), had been a revolution for the treatment of chronic myeloid leukemia (CML) and had greatly enhanced patient survival.